initial public offerings (IPOs) trading on American exchanges

Sunday, June 28, 2015

EQT GP Holdings (EQGP) began trading on the NYSE on 12 May 2015


EQT GP Holdings, LP is a limited partnership formed to own partnership interests in EQT Midstream Partners, LP (EQM), a growth-oriented limited partnership formed by EQT Corporation (EQT) to own, operate, acquire and develop midstream assets in the Appalachian Basin. EQT Midstream Partners, LP provides midstream services to EQT Corporation and third-party companies through its strategically located transmission, storage, and gathering systems that service the Marcellus and Utica regions. EQT Midstream Partners, LP owns 700 miles and operates over 200 miles of federal energy regulatory commission (FERC)-regulated interstate pipelines and also owns over 1,500 miles of high- and low-pressure gathering lines. The Company's projects include Equitrans Expansion, Mountain Valley Pipeline and Ohio Valley Connector.


Address

625 Liberty Ave Ste 1700
PITTSBURGH, PA 15222-3114
United States

Yelp (YELP) : 3-year performance

monthly, 3 years

daily, 4 months

Saturday, June 27, 2015

IPOs this week : June 29 - July 2, 2015

Five companies, including three in health care, are set to go public in the coming week.

  • The largest is LoanCore Realty Trust, a REIT that plans to offer 15 million shares at 20. 
  • ConforMIS, which makes knee replacement implants, plans to raise about $135 million by offering 9 million shares.

Update June 30, 2015: LoanCore Realty Trust, a commercial mortgage REIT backed by Jefferies and GIC, postponed its IPO on Tuesday, citing poor market conditions. 

AppFolio (APPF) began trading on the NASDAQ on 26 June 2015

AppFolio (NASDAQ:APPF), a provider of a cloud-based platform for managing rental properties and legal cases, climbed 17% after pricing at the low end of the expected range. It raised $74 million.


AppFolio, Inc. is a provider of cloud-based software solutions for small and medium-sized businesses (SMBs) in the property management and legal industries or verticals. The Company's mobile-optimized software solutions have an interface across multiple devices, enabling its customers to work at any time and from anywhere. The Company's property management software provides small and medium-sized property managers with an end-to-end solution to their business needs, enabling them to manage properties in a single, integrated environment. The Company's legal software provides solo practitioners and small law firms with a streamlined practice and case management solution, allowing them to manage their practices and case load within a flexible system. The Company also offers its professionally designed Websites and electronic payment services to property manager and law firm customers.

Address

50 Castilian Dr
GOLETA, CA 93117-3080
United States 

Alarm.com (ALRM) began trading on the NASDAQ on 26 June 2015

Alarm.com (NASDAQ:ALRM), a developer of connected home technology, rose 20.6% after pricing at the midpoint of expectations. It raised $98 million.


Description

Alarm.com Holdings, Inc. is a platform solution for the connected home. The Company, through its cloud-based services, makes connected home technology accessible to millions of home and business owners. The Company's multi-tenant software-as-a-service (SaaS) platform enables home and business owners to secure their properties and automate and control an array of connected devices through a single, intuitive user interface. The Company offers four primary solutions, which include interactive security, intelligent automation, video monitoring and energy management. The Company offers a suite of enterprise-grade business management solutions to its service providers, which include service provider portal, installation and support, business management, and sales, marketing and training. The Company is also engaged in the design and manufacturing of various types of hardware, including cellular communication modules, image sensor, video cameras and smart thermostat.

Address

8150 Leesburg Pike
VIENNA, VA 22182
United States

Key stats and ratios

Q1 (Mar '15)2014
Net profit margin6.61%8.07%
Operating margin11.14%12.55%
EBITD margin-14.94%
Return on average assets9.85%12.25%
Return on average equity--
Employees400

Green Plains Partners LP (GPP) began trading on the NASDAQ on 26 June 2015

Green Plains Partners (NASDAQ:GPP), a master limited partnership that owns and operates ethanol transportation and storage assets.


Green Plains Partners LP owns, operates, develops and acquires ethanol and fuel storage tanks, terminals, transportation assets and other related assets and businesses. The Company operates through four segments: production of ethanol and distillers grains (ethanol production); corn oil production; grain handling and storage and cattle feedlot operations (agribusiness), and marketing, merchant trading and logistics services for self-produced and third-party ethanol, distillers grains, corn oil and other commodities (marketing and distribution). The Company's parent company is Green Plains Inc. The Company owns and operates approximately 27 ethanol storage tanks. Its ethanol storage assets are engaged in storing and loading the ethanol that its parent produces at its ethanol production plants. It provides terminal services and logistics solutions through its fuel terminal facilities. Its transportation assets include a leased railcar fleet of approximately 2,200 railcars.

Address

450 Regency Pkwy Ste 400
OMAHA, NE 68114-3701
United States

CDW (CDW) : 2-year performance

weekly

monthly

Friday, June 26, 2015

Xactly (XTLY) began trading on the NYSE on 26 June 2015

Xactly (NYSE:XTLY) priced below views and gained 9% Friday. The provider of a cloud-based incentive compensation platform designed to improve employee productivity raised $56 million.


 



Description



Xactly Corporation provides enterprise-class, cloud-based, incentive compensation solutions for employee and sales performance management. The Company focuses on the incentive compensation and employee, and sales performance management market. It offers solutions to incentivize employees and align their behaviors with company goals. Its solutions allow organizations to make decisions, optimize behaviors and design incentive compensation plans. It delivers its solutions through a software-as-a-service business model. Its solutions enable executives design, manage and analyze incentive programs and provide visibility into employee and incentive program performance. Its solutions enable employees to monitor, estimate and track their own and their team's performance in real-time, and modify their behaviors. Its solutions automate various processes, such as estimating and calculating commissions and bonuses, assigning sales territories, forecasting accruals and modeling business outcomes.

Address

225 W Santa Clara St Ste 1200
SAN JOSE, CA 95113-1748
United States 

Key stats and ratios

Q2 (Apr '15)2015
Net profit margin-28.02%-30.33%
Operating margin-20.47%-25.31%
EBITD margin--22.09%
Return on average assets--40.09%
Return on average equity--
Employees345

Glaukos (GKOS) began trading on the NYSE on 25 June 2015

Glaukos (NYSE:GKOS) is developing surgical devices for treating glaucoma. It priced 6 million shares at an above-range 18. The stock popped 73% to 31.22 in its debut Thursday. It fell 10% Friday.






Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.


Address

26061 Merit Cir Ste 103
LAGUNA HILLS, CA 92653-7010
United States 

Seres Therapeutics (MCRB) began trading on the NASDAQ on 26 June 2015

No Profit, No Sales, No Prob
  • Seres is developing a class of biological drugs to treat metabolic, inflammatory and infectious diseases. Among its leading candidates is SER-109, a treatment for large-intestine inflammation.
  • As is typical of biotech companies that come public, Seres has no revenue or profit. Also typical, investors are betting that its therapies under development will produce blockbuster sales.


Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. It's SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Address

215 First Street, Suite 440
CAMBRIDGE, MA 2142
United States

Saturday, June 20, 2015

MINDBODY (MB) began trading on the NASDAQ on 19 June 2015

  • Mindbody (MB), the software provider for fitness studios, went public on the Nasdaq on Friday, after raising $100 million in its IPO.
  • The San Luis Obispo, Ca.-based company provides payments software and online scheduling platforms for 42,000 health and wellness businesses globally and has gained significant traction with yoga studios. Clients include ClassPass, Bikram Yoga, and New York Health & Racquet Club.




  • MINDBODY, Inc. is a company that operates an online wellness services marketplace with over 42,000 local business subscribers. Through its integrated cloud-based business management software and payments platform, the Company enables businesses to manage class and appointment schedules, staff members, client information, online bookings, inventory, payroll and retail sales. The Company also offers marketing and client retention capabilities to help businesses acquire and retain their clients, and analytics capabilities to help them improve their businesses and plan for the future. It connects consumers with local businesses through its MINDBODY Connect platform, which powers a mobile interface that allows consumers to discover, evaluate, book and pay for wellness services, whether they are near their homes or traveling. Its Connect Workplace offering extends its platform to corporate employers. Its applications and add-ons include MINDBODY Express and Engage by MINDBODY Connect.


    Address

    4051 Broad St Ste 220
    SAN LUIS OBISPO, CA 93401-8723
    United States

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin-35.31%-35.15%
    Operating margin-34.37%-34.38%
    EBITD margin--27.85%
    Return on average assets-43.75%-47.42%
    Return on average equity--
    Employees1,100

    Fogo De Chao (FOGO) began trading on the NASDAQ on 19 June 2015

    • The chain operates 26 restaurants in the U.S., 10 in Brazil and one in Mexico. The company reported revenue of $262.3 million in 2014, up 19% from the prior year, and net income of $17.3 million.


    Description

    Fogo de Chao, Inc. is a United States-based holding company. The Company, through its subsidiaries, operates upscale Brazilian churrascaria steakhouses under the brand of Fogo de Chao. The Company owns 100% of Brasa (Purchaser) Inc. (Brasa Purchaser), which owns 100% of Brasa (Holdings) Inc. (Brasa Holdings). The Company operates through two segments: United States and Brazil. It specializes in fire-roasting meats utilizing the centuries-old Southern Brazilian cooking technique of churrasco. The Company offers its guests a tasting menu of meats featuring up to 20 cuts, simply seasoned and fire-roasted to expose their natural flavors. The Company operates approximately 26 restaurants in the United States, 10 in Brazil and one in Mexico. The Company operates a range of restaurant formats, including in-line and free-standing locations. Its restaurants range in size from approximately 7,000 to 16,000 square feet, with seating from 200 to 500 guests.

    Address

    14881 Quorum Dr Ste 750
    DALLAS, TX 75254-7051
    United States

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin6.94%6.59%
    Operating margin14.65%15.78%
    EBITD margin-21.40%
    Return on average assets3.86%3.60%
    Return on average equity12.57%11.53%
    Employees2,515

    Friday, June 19, 2015

    David's Tea (DTEA) posts first quarter loss, shares crash 25% (6/15)

    David’s Tea lost 93.2 million Canadian dollars, an equivalent of $75.7 million. The company also reported a loss of C$7.73 per diluted share. Excluding the IPO and other one-time costs, net income was reported as C$1.1 million, dropping from C$1.4 million in the first quarter of 2014.

    The earnings report also pointed to the operating costs of a weaker Canadian dollar as a reason for the loss.

    (chart Dec 2016)

    Company had it's IPO just 2 weeks ago


    Thursday, June 18, 2015

    Fitbit (FIT) began trading on the NYSE on 18 June 2015


  • The largest tech IPO this year, Fitbit raised $732 million on its June 18 debut. 
  • Fitbit priced 36.6 million shares at 20 each, above its upwardly revised expected range of 17 to 19.
  • Fitbit stock popped 48% on its first day of trading.






  • Fitbit, Inc. is a provider of health and fitness products. The Company's Fitbit platform combines connected health and fitness devices with software and services, including an online dashboard and mobile applications, data analytics, motivational and social tools, personalized insights, and virtual coaching through fitness plans and interactive workouts. It offers a number of fitness products, including Fitbit Zip, Fitbit One, Fitbit Flex, Fitbit Charge, Fitbit Charge HR, Fitbit Surge and Aria. Its wrist-based and clippable devices automatically track users’ daily steps, calories burned, distance traveled, floors climbed, and active minutes and display real-time feedback to encourage them to become more active in their daily lives. Fitbit Premium is its membership that serves as an around the clock virtual personal trainer delivered to users through any Web browser. It operates FitStar, a provider of interactive video-based exercise experiences on mobile devices and computers.

    Address

    405 Howard St
    SAN FRANCISCO, CA 94105-2625
    United States 

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin14.25%17.68%
    Operating margin26.71%21.19%
    EBITD margin-22.01%
    Return on average assets-30.51%
    Return on average equity-480.64%

    Wednesday, June 17, 2015

    Nivalis Therapeutics (NVLS) began trading on the NASDAQ on 17 June 2015


    Description

    Nivalis Therapeutics, Inc. is a United States-based clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of product candidates for patients with cystic fibrosis. The Company has developed a portfolio of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), which is used to increase and prolong cystic fibrosis transmembrane conductance regulator (CFTR) activity and to decrease inflammation. Its drug candidate portfolio consists of various compounds for oral, intravenous (IV) or inhaled administration. The Company’s lead clinical candidate is N91115, which is an investigational small molecule that addresses a defect in CFTR, resulting from mutations in the CFTR gene. N91115 is designed to stabilize CFTR inside the cell and at the cell surface. N91115 is a CFTR stabilizer that modulates CFTR activity.

    Address

    3122 Sterling Cir Ste 200
    BOULDER, CO 80301-2609
    United States

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin--
    Operating margin--
    EBITD margin--
    Return on average assets-63.10%-89.71%
    Return on average equity--
    Employees23

    Monday, June 15, 2015

    TransUnion files for an IPO to raise up to $781.5 million

    TransUnion has filed to sell 29.55 million shares in an initial public offering, which the provider of consumer reports, risk scores and analytical services expects to price at $21 to $23 a share. The company has applied to list on the New York Stock Exchange with the ticker symbol "TRU" .

    The lead underwriter of the IPO are Goldman Sachs, J.P. Morgan, BofA Merrill Lynch and Deutsche Bank Securities. The underwriters will have the option to buy up to an additional 4.43 million shares to cover over-allotments. The proposed maximum amount to be raised is $781.5 million. After the IPO is completed, Advent International and Goldman Sachs will still own a majority of the outstanding shares.

    Saturday, June 13, 2015

    KemPharm (KMPH) began trading on the NASDAQ on 16 April 2015


    KemPharm, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company, through its Ligand Activated Therapy (LAT) platform technology, creates NME prodrug product candidates. The Company's NME prodrug product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD), and KP303 for the treatment of central nervous system (CNS) disorders. The Company's product's KP201/APAP is in clinical trial stage, and KP511/ER, KP415, KP606/ER and KP303 are in preclinical trail stage.

    Address

    2656 Crosspark Road, Suite 100
    CORALVILLE, IA 52241
    United States

    Adaptimmune Therapeutics (ADAP) began trading on the NASDAQ on 7 May 2015


    Description

    Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer T-cell receptors (TCRs), and produce TCR therapeutic candidates for administration to patients. The Company's target peptides are NY-ESO-1 and MAGE A-10. The Company's affinity-enhanced TCR therapeutics targets the NY-ESO-1, or NY-ESO, cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate, in patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.

    Address

    91 Park Drive
    ABINGDON, OX14 4RY
    United Kingdom

    Key stats and ratios

    Q4 (Dec '14)2014
    Net profit margin-127.81%-2100.84%
    Operating margin-211.14%-2376.90%
    EBITD margin--2335.49%
    Return on average assets--44.15%
    Return on average equity--
    Employees78

    Etsy (ETSY) : 2-month performance


    Biotie Therapies (BITI) began trading on the NASDAQ on 11 June 2015

    • Biotie has a commercial stage therapy for alcohol dependence, but its lead drug is a Parkinson's Disease treatment.
    • Biotie plans to raise $56 million by offering 4 million American Depositary Shares at a price of 14.82, under the ticker BITI. The lead underwriters are RBC Capital Markets and Stifel.


    Biotie Therapies Corp (BITI) is a commercial stage biotech with a very diverse pipeline of clinical stage drugs. The company is currently publicly traded in Finland. The ADS shares will exchange at an 80:1 ratio to the Finnish shares. The resulting fully diluted market cap after the ADS IPO will be about $180 million assuming current Dollar to Euro exchange rates and an ADS price just below $15 per share. The company currently has one commercial drug in Europe as well as several others in the pipeline, and is targeting commercialization in the U.S.

    Pipeline

    Biotie currently has one commercial stage product, which it has licensed to Lundbeck for exclusive selling rights. The drug, Selincro, is a treatment for chemical alcohol dependence, and is currently sold in 29 European countries and is targeting U.S. approval and commercialization. However, the drug is a very small source of revenue and is not the major selling point for investors. Rather investors will be interested in the upside potential of the remaining pipeline of clinical trial drugs.

    Wingstop (WING) began trading on the NASDAQ on 12 June 2015


    Wingstop President & CEO Charles Morrison in center.



    Description

    Wingstop Inc. (Wingstop) is a franchisor and operator of restaurants that specializes in hand-sauced and tossed chicken wings. The Company offers around 11 flavors on its bone-in and boneless chicken wings paired with hand-cut, seasoned fries and sides made fresh daily. The Company operates business through two segments, which include Franchise segment and Company segment. The Company's Franchise segment consists of its domestic and international franchise restaurants. Its franchise operations segment consists of approximately 693 restaurants, which are operated by its Wingstop franchisees in the United States and five countries outside of the United States. The Company's Company segment consists of Company-owned restaurants, which are located in the United States.

    Address

    5501 Lyndon B Johnson Fwy Fl 5
    DALLAS, TX 75240-6225
    United States 

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin13.42%13.32%
    Operating margin26.02%26.78%
    EBITD margin-31.09%
    Return on average assets8.74%7.69%
    Return on average equity--
    Employees111

    Bojangles (BOJA) reported first earnings since IPO


    Charlotte-based chicken-and-biscuit chain Bojangles reported first quarter earnings per share of 17c, beating analysts' expectations of 15c, on revenue that increased 19.2% from the year ago quarter to $114.6M, which was also higher than analysts' estimates of $114.48M. The restaurant chain, which opened 16 new restaurants during the quarter, saw its system-wide comparable restaurant sales increase 7.9% compared to the first quarter of 2014. For fiscal year 2015, the company expects to report revenue of between $480M-$487M. Analysts were forecasting revenue of $486.6M. Bojangles guided for FY15 system-wide comparable restaurant sales growth of low to mid-single digits. In FY15, the company expects the opening of 50-57 system-wide restaurants, consisting of 22-25 new company-operated restaurants and 28-32 new franchised restaurants. Operating income for the chain decreased 7.2% to $9.5M in Q1 down from $10.2M in the year-ago quarter primarily due to a $2.7M increase in costs related to its initial public offering.

    Friday, June 12, 2015

    Fortress Transportation and Infrastructure Investors (FTAI) began trading on the NYSE on 15 May 2015



    Description

    Fortress Transportation and Infrastructure Investors LLC owns and acquires infrastructure and related equipment for the transportation of goods and people across the world. The Company's strategic business units include infrastructure and equipment leasing. Its segments include Aviation Leasing, Offshore Energy, Shipping Containers, Jefferson Terminal and Railroad. The Company's Aviation Leasing, Offshore Energy, Shipping Containers segments are within equipment leasing business, and Jefferson Terminal and Railroad segments, together include the infrastructure business. The Company's equipment leasing business acquires assets that are used to carry cargo or people or provide functionality to transportation infrastructure. Its infrastructure business acquires long-life assets or operating businesses that provides services to transportation networks.

    Address

    1345 Avenue of the Americas
    NEW YORK, NY 10105-0302
    United States

    Key stats and ratios

    Q1 (Mar '15)2014
    Net profit margin5.72%5.04%
    Operating margin2.20%-17.41%
    EBITD margin-40.11%
    Return on average assets0.55%0.35%
    Return on average equity3.43%1.93%

    EndoChoice (GI) : 1-week performance


    Shopify (SHOP) : 3-week performance


    Thursday, June 11, 2015

    Axovant Sciences (AXON) began trading on the NYSE on 11 June 2015

    • The biggest U.S. biotech IPO ever. 
    • Axovant Sciences sold shares at $15 a piece, raising $315 million at a $1.4 billion valuation. Already, the stock is up 90%, giving Axovant a valuation of about $2.8 billion.
    • Behind the massive IPO is a 29-year-old former hedge fund manager, Vivek Ramaswamy, who previously worked as a partner at Dan Gold’s QVT. 
    • He left the hedge fund firm last year and founded Roivant, in which QVT is an investor. Axovant was formed in October and spun off by Roivant.
    • In December 2014, Ramaswamy engineered the purchase of an experimental Alzheimer’s pill from GlaxoSmithKline for $5 million. It is Axovant’s sole asset. GlaxoSmithKline also obtained a 12.5% royalty based on net sales and Axovant is obligated to pay the drug giant tens of millions of dollars more if certain milestones are achieved.

    Shares of Axovant Sciences nearly doubled in value after the dementia drug developer said its initial public offering raised $315 million, more than Axovant had expected.

    The company expanded its offering to 21 million shares and said the offering priced at $15 a share, at the high end of its estimates.

    The stock climbed $14.90, or 99.3 percent, to end its first trading day at $29.90. It peaked at $31.17.

    The offering values Axovant at around $1.4 billion. The Bermuda-based company is controlled by Roivant Sciences Ltd., which invests in biotech companies with late-stage experimental drugs. Roivant owns about 80 percent of Axovant's shares.

    Ramaswamy is bringing his family along for the ride. His mother and brother are both employees of Axovant Sciences and have received some 1 million stock options between them that carry an exercise price of 90 cents per share. “They are both physicians by training, one of them has been a geriatric physiatrist who has treated patients with Alzheimer’s disease for a couple of decades,” says Ramaswamy. “Like all of our employees they have received stock options.”

    Description



    Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. The Company develops RVT-101, a product candidate for the treatment of Alzheimer's disease and other forms of dementia. Its RVT-101 is an orally administered, potent antagonist of the 5-hydroxytryptamine 6 (5-HT6) serotonin receptors in the brain. By antagonizing the 5-HT6 receptor, RVT-101 enhances the release of acetylcholine, glutamate and other neurotransmitters that are essential to cognition. The Company's RVT-101 has shown safety, tolerability and efficacy for up to 48 weeks, as demonstrated in a 684-subject, randomized, placebo-controlled Phase IIb trial.

    Address

    Clarendon House, 2 Church Street
    HAMILTON, HM11
    Bermuda
    +1-441-5328833 (Phone)